McDermid RC, Raghunathan K, Romanovsky A, Shaw AD, Bagshaw SM. Controversies in fluid therapy: Type, dose and toxicity. World J Crit Care Med 2014; 3(1): 24-33 [PMID: 24834399 DOI: 10.5492/wjccm.v3.i1.24]
Corresponding Author of This Article
Dr. Sean M Bagshaw, Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C. Mackenzie Centre, 8440-122 ST NW, Edmonton, AB T6G2B7, Canada. bagshaw@ualberta.ca
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Crit Care Med. Feb 4, 2014; 3(1): 24-33 Published online Feb 4, 2014. doi: 10.5492/wjccm.v3.i1.24
Controversies in fluid therapy: Type, dose and toxicity
Robert C McDermid, Karthik Raghunathan, Adam Romanovsky, Andrew D Shaw, Sean M Bagshaw
Robert C McDermid, Adam Romanovsky, Sean M Bagshaw, Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G2B7, Canada
Karthik Raghunathan, Andrew D Shaw, Department of Anesthesiology, Duke University Medical Center/Durham VAMC, Durham, NC 90484, United States
Andrew D Shaw, Department of Critical Care Medicine, Duke University Medical Center/Durham VAMC, Durham, NC 90484, United States
Author contributions: All the authors contributed to drafting and critical revision of manuscript.
Supported by Canada Research Chair in Critical Care Nephrology; Clinical Investigator Award from Alberta Innovates-Health Solutions to Bagshaw MS
Correspondence to: Dr. Sean M Bagshaw, Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C. Mackenzie Centre, 8440-122 ST NW, Edmonton, AB T6G2B7, Canada. bagshaw@ualberta.ca
Telephone: +1-780-4076755 Fax: +1-780-4071228
Received: June 7, 2013 Revised: October 30, 2013 Accepted: December 12, 2013 Published online: February 4, 2014 Processing time: 254 Days and 23 Hours
Core Tip
Core tip: Fluid therapy is exceedingly common in acutely ill patients; however, numerous questions on the efficacy and safety of fluid therapy in terms of the type and dose remain. Fluid therapy prescription is context-specific and any fluid type can be harmful if administered inappropriately. When considering crystalloids versus colloids, differences in efficacy are modest but the risk of kidney toxicity and bleeding complications with hydroxyethyl starch appear more significant. The differences in chloride load across crystalloid solutions appears to have physiologic and clinically important effects, in particular for contributing to hyperchloremic metabolic acidosis, kidney injury and greater utilization of renal replacement therapy associated with 0.9% saline. Fluid therapy should be viewed as analogous to the prescription of any drug in acutely ill patients.